Facebook
Twitter
LinkedIn
ForwardCastration-Resistant Prostate Cancer (CRPC) Live Forum for Urology Residents & Fellows (2017): Required Pre-Requisites
The AUA recently released a report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in the area of CRPC. Additionally, the findings indicate that the AUA should look into the feasibility of developing stand-alone courses and educational materials specifically targeted to residents that covers the medical management of advanced prostate cancer.
Based on this educational need, AUA is launching a new educational initiative to focus on CRPC Resident & Fellow Training. Based on the documented need for additional education in this area, the AUA has developed multiple educational interventions to improve the urology resident and fellow's ability to care for patients with CRPC. The CRPC Resident & Fellow Training initiative is comprised of a variety of unique activities, including a self-assessment, pre-requisite work, a live forum and an online case-study activity. This activity will also provide each participant will access to patient education resources The initiative will offer the live one-day forum five times to reach residents and fellows across the country.
This initiative will provide a foundation of knowledge on CRPC and the ability to apply this knowledge into practice to improve the outcomes of their patients. As residency programs differ in what is offered, we recommend that each participant in this initiative successfully complete all of the activities. If a resident successfully completes all activities, they will receive a Certificate of Participation which they may share with their Residency Program Director.
All activities are free to urology residents and fellows.
Activity 2 – Live Forum Pre-Requisite Activities
Following the self-assessment and analysis of their results, but prior to the live forum, participants will be given access to online content to prepare them for the content which will be examined at the live forum. Free access will be provided on AUAUniversity once the participant has registered for a live forum and completed the self-assessment.
Target Audience
- Urology Fellows
- Residents
Course Co-Directors:
Michael Cookson, MD, MMHC
David Jarrard, MD
| Faculty | Company | Role | Financial | Date Disclosed |
|---|---|---|---|---|
| Michael S. Cookson, MD | TesoRx Pharma LLC | Consultant or Advisor | Yes | 02/24/2017 |
| Michael S. Cookson, MD | Janssen Biotech, Inc. | Consultant or Advisor | Yes | 02/24/2017 |
| Michael S. Cookson, MD | Myovant Sciences | Consultant or Advisor | Yes | 01/18/2018 |
| Michael S. Cookson, MD | MDxHealth | Consultant or Advisor | Yes | 06/01/2017 |
| Michael S. Cookson, MD | Bayer Healthcare Pharmaceuticals | Consultant or Advisor | Yes | 01/18/2018 |
| David F. Jarrard, MD | Gregor Diagnostics | Consultant or Advisor | No | 12/18/2016 |
ACCREDITATION
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION
The American Urological Association designates this live activity and enduring material for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education
- Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.